Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients
Conclusion
This first description of CYP3A4*20 null genotype in liver-transplanted patients, supports the relevance of CYP3A genotyping in tacrolimus therapy.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
More News: Liver | Liver Transplant | Prograf | Spain Health | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology